Can My Myelofibrosis Risk Score Change Over Time?

Yes, your myelofibrosis risk score may change over time. A risk category is not a permanent label; rather, it is a “snapshot” of your disease at a specific moment ^[1]. Because myelofibrosis can evolve, risk scores are recalculated when clinically appropriate to reflect your current test results and symptoms rather than those you had at diagnosis ^[2]. However, a changing score does not automatically mean your disease has progressed, and a single abnormal lab value does not dictate your treatment ^[1][3].

Why Different Scores Are Used

There is no single “best” risk score. Your care team selects a scoring system based on how your disease originated, your age, and the genetic information available. Each system calculates risk using a different mix of factors ^[4]:

• DIPSS and DIPSS-plus: These are used for primary myelofibrosis (myelofibrosis that did not develop from another condition). They rely on current clinical features, including age over 65, hemoglobin under 10 g/dL, a white blood cell count over 25 × 10⁹/L, circulating peripheral-blood blasts (immature cells) of 1% or higher, and the presence of constitutional symptoms (fever, drenching night sweats, and unexplained weight loss) ^[1]. DIPSS-plus also factors in red blood cell transfusion dependence, platelets under 100 × 10⁹/L, and an unfavorable karyotype (chromosome analysis) ^[1].
• MIPSS70 and MIPSS70-plus: These models were originally developed for transplant-age patients (age 70 or younger) with primary myelofibrosis ^[5]. Alongside clinical factors, they incorporate marrow scarring (fibrosis) and specific high-risk gene mutations (such as ASXL1 or SRSF2) ^[5]. Newer versions, such as MIPSS70+ v2.0, adjust variables further and use updated cytogenetic risk categories ^[6].
• MYSEC-PM: This tool is validated and preferred for secondary myelofibrosis—meaning the disease evolved from a prior blood disorder like essential thrombocythemia (ET) or polycythemia vera (PV) ^[7]. Because secondary myelofibrosis behaves differently, this customized tool provides a more accurate assessment of your specific disease path ^[8].

Depending on the tool, patients are usually grouped into categories like Low, Intermediate-1, Intermediate-2, or High risk. These categories help estimate overall prognosis for large populations, but they do not predict your exact personal timeline ^[9][1].

What Triggers a Reassessment?

Your doctor will not calculate a new score for every single lab fluctuation, as isolated changes can be due to treatment effects, bleeding, or temporary laboratory variations. Instead, they look for confirmed clinical trends ^[1]:

• Persistent blood count changes: A confirmed, ongoing drop in hemoglobin or platelets.
• Rising blasts: Blasts are immature blood cells. If blasts in your peripheral blood or bone marrow reach 10–19%, the disease is considered in an “accelerated phase,” and 20% or more indicates a “blast phase” (leukemic transformation) ^[10]. If a lab report shows new or rising blasts, contact your hematology team promptly—do not wait for your next routine appointment ^[11].
• New constitutional symptoms: The confirmed development of fever, night sweats, or weight loss ^[1]. (Note: An enlarging spleen is important for monitoring symptoms and treatment response, but it is not a direct input for DIPSS models).
• Clonal Evolution: This is the emergence of additional abnormal cell populations. While not checked at every visit, repeat genetic testing might reveal new mutations that have developed over time ^[2].

How Risk Scores Inform Treatment

Risk scores are prognostic aids, not automatic treatment rules. Your treatment plan depends on your symptoms, blood counts, overall fitness, and personal goals ^[3].

Stem Cell Transplant Decisions

An allogeneic (donor-derived) stem cell transplant is the only potential cure for myelofibrosis, but it carries substantial physical risks ^[12]. You do not need to wait for your score to reach High or Intermediate-2 to speak with a transplant specialist. Early consultation can be highly valuable even if your score is Low or Intermediate-1, especially if you have adverse mutations, worsening blood counts, or an unfavorable disease trajectory ^[13]. Meeting a specialist early allows you to explore donor options and assess your fitness before the disease advances, without committing you to the procedure ^[13].

Medical Therapy

A changing score does not automatically require a medication switch. For example, your doctor might prescribe specific JAK inhibitors (targeted medications that block certain inflammatory signals driving the disease) based on your overall symptom burden, prior drug exposure, and whether your primary issue is an enlarged spleen, severe anemia, or low platelets ^[3][14]. The goal of medical therapy is to improve your daily quality of life and manage symptoms, not simply to treat a number on a risk score ^[3].